*Proposed mechanism of BiTE®
BiTE
Engaging the immune system
to target malignant cells
Bispecific T cell Engager (BiTE®) technology is an innovative
investigational approach that is designed to help engage
the body's endogenous T cells to target malignant cells.1,2,*
Mechanism of BiTE® Antibody Video
FUTURE OF BiTE®

The BiTE® antibody construct is designed to help engage
the body's endogenous T cells to target malignant cells 2,8

BiTE®-activated T cells target malignant cells that can lead to subsequent expansion of local cytotoxic T-cell population in targeting additional
malignant cells.9,11

The BiTE® antibody construct is designed with the goal of overcoming malignant cells' evasion of the immune system by:*

  • Engaging endogenous T cells, thereby avoiding the need for ex vivo expansion or manipulation10
  • Not relying on the generation of specific T-cell clones, on the activity of costimulatory molecules, or on normal antigen presentation8,9

THE CLINICAL EFFECTIVENESS OF BiTE® IS CURRENTLY BEING INVESTIGATED BY AMGEN.

Visit www.amgenoncology.com to learn more.